Chee Khoon Lee

University of Sydney

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (5)

Wendy A Cooper

Keunchil Park

The University of Texas MD Anderson Cancer Center

UNITED STATES

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES

Sarah (Sally) J Lord

Associate Professor, Research

The University of Notre Dame Australia

Harold Hudson

Emeritus Professor

Macquarie University

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Chee Khoon Lee

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (5)

Wendy A Cooper

Keunchil Park

Catherine Shu

Sarah (Sally) J Lord

Harold Hudson

Make your next move.

Chee Khoon Lee

Research Interests

Explore related searches

Contact this professor

Articles (20)

Navigating advanced lung cancer care, patient–physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians

Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.

Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer.

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC.

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.

Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations

Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).

Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

MANAGEMENT PARADIGM OF CENTRAL NERVOUS SYSTEM METASTASES IN NON-SMALL CELL LUNG CANCER: AN AUSTRALIAN PERSPECTIVE

Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis

PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer

The validity of progression‐free survival 2 as a surrogate trial end point for overall survival

Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

Collaborators (5)

Wendy A Cooper

Keunchil Park

Catherine Shu

Sarah (Sally) J Lord

Harold Hudson

Make your next move.